Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × cediranib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 8 Rectal Neoplasms 6 Colonic Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 4 Lung Neoplasms 3 Carcinoma, Hepatocellular 3 Stomach Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Carcinoma, Renal Cell 2 Breast Neoplasms, Male 2 Brain Neoplasms 2 Sarcoma 1 Oligodendroglioma 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Gallbladder Neoplasms 1 Ependymoma 1 Choriocarcinoma 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1

Interventions

Gemcitabine 82 Cisplatin 65 Capecitabine 34 Oxaliplatin 31 durvalumab 29 pembrolizumab 24 Fluorouracil 23 Leucovorin 22 S 1 (combination) 16 lenvatinib 12 Nivolumab 12 Irinotecan 12 tremelimumab 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 9 Injections 7 Immune Checkpoint Inhibitors 7 Docetaxel 7 apatinib 6 Trastuzumab 6 titanium silicide 5 surufatinib 5 irinotecan sucrosofate 5 camrelizumab 5 Folfox protocol 5 Drug Therapy 5 Carboplatin 5 Blood Specimen Collection 5 Albumin-Bound Paclitaxel 5 zanidatamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00939848 2014-10-27

ABC-03

University College, London

Phase 2/3 Completed

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡